Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article
Abstract
Background: Heart disease is one of the most common chronic disease and leading cause of morbidity and mortality worldwide. Adropin, a newly identified protein, is important for energy homeostasis and maintaining insulin sensitivity, and has been referred to as a novel regulator of endothelial cells. Endothelial dysfunction is a key early event in atherogenesis and onset of HD. Therefore, this review gives a systematic overview of studies investigating plasma adropin level in patient with heart disease.
Methods: Data carried out in PubMed, Scopus, Web of Science, Embase, Google scholar and MEDLINE, from the earliest available online indexing year through 2015. The search restricted to studies conducted in humans. The keyword search was adropin to apply in title, abstract and keywords. References lists of all original published articles were scanned to find additional eligible studies.
Results: Heart failure (HF), coronary atherosclerosis acute myocardial infarction and Cardiac Syndrome X (CSX) were type of heart disease acknowledged in this study. Majority of evidences introduced low adropin as an independent risk factor of heart disease. In a case-control study, the plasma level of adropin increased with the severity of HF.
Conclusion: Adropinmay be a potential serum biomarker for early diagnosis of HD.
Fuster V, Kovacic JC (2014). Acute Coronary Syndromes Pathology, Diagnosis, Genetics, Prevention, and Treatment. Circ Res,114(12):1847-51.
Pope JH, Aufderheide TP, Ruthazer R, Woolard RH, Feldman JA, Beshansky JR, et al (2000). Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med, 342(16):1163-70.
Swap CJ, Nagurney JT (2005). Value and limitations of chest pain history in the evaluation of patients with suspected acute coronary syndromes. JAMA, 294(20):2623-9.
Vasan RS (2006). Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation, 113(19):2335-62.
Kumar KG, Trevaskis JL, Lam DD, Sutton GM, Koza RA, Chouljenko VN, et al (2008). Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab, 8(6):468-81.
Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Gupta M, et al (2010). Adropin is a novel regulator of endothelial function. Circulation, 122(11 Suppl):S185-92.
Kathir K, Adams MR, (2003). Endothelial dysfunction as a predictor of acute coronary syndromes. Semin Vasc Med, 3(4): 355-362.
Wu L, Fang J, Chen L, Zhao Z, Luo Y, Lin C, et al. (2014). Low serum adropin is associated with coronary atherosclerosis in type 2 diabetic and non-diabetic patients. Clin Chem Lab Med, 52(5):751-8.
Kumar G, Halem H, Culler M, Stephens J, Mynatt R, Butler A (2008). Adropin-a Novel Secreted Factor Involved in Lipid Homeostasis.Obesity, nature publishing group 75 varick st, 9thflr, New York, NY10013-1917 USA.
Kumar K, Zhang J, Mynatt R, Butler A (2009). Adropin-a novel secreted factor linking diet with energy homeostasis. Biopolymers,John Wiley & Sons Inc 111 river st, Hoboken, New Jersi,NJ 07030 USA.
Sanchis-Gomar F, Alis R, Rampinini E, Bosio A, Ferioli D, La Torre A, et al (2015). Adropin and apelin fluctuations throughout a season in professional soccer players: Are they related with performance? Peptides, 70:32-6.
Chen M, Ouyang F, Zhou S (2015). Adropin as a novel energy factor likely has the ability to regulate blood pressure. Med Hypotheses, 85(2):234.
Ganesh‐Kumar K, Zhang J, Gao S, Rossi J, McGuinness OP, Halem HH, et al (2012). Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring), 20(7):1394-402.
Lian A, Wu K, Liu T, Jiang N, Jiang Q (2016). Adropin induction of lipoprotein lipase expression in tilapia hepatocytes. J Mol Endocrinol, 56(1):11-22.
Kumar KG, Jingying Z, Mynatt RL, Butler AA, editors (2010). Adropin Is Required for Maintaining Glucose Homeostasis. Diabetes, amer diabetes assoc 1701 n beauregard st, alexandria,Vancover, VA 22311-1717 USA.
Yildirim B, Celik O, Aydin S (2014). Adropin: a key component and potential gatekeeper of metabolic disturbances in policystic ovarian syndrome. Clin Exp Obstet Gynecol, 41(3):310-2.
Fujie S, Hasegawa N, Sato K, Fujita S, Sanada K, Hamaoka T, et al (2015). Aerobic exercise training-induced changes in serum adropin level are associated with reduced arterial stiffness in middle-aged and older adults. Am J Physiol Heart Circ Physiol, 309(10):H1642-47.
Gozal D, Kheirandish-Gozal L, Bhattacharjee R, Molero-Ramirez H, Tan H-L, Bandla HP (2013). Circulating adropin concentrations in pediatric obstructive sleep apnea: potential relevance to endothelial function. J Pediatr, 163(4):1122-6.
Nergiz S, Altinkaya SO, Kurt Ömürlü İ, Yuksel H, Küçük M, Demircan Sezer S (2015). Circulating adropin levels in patients with endometrium cancer. Gynecol Endocrinol, 31(9):730-5.
Zapata RC, Salehi R, Ambrose DJ, Chelikani PK (2015). Effects of prepartum fat supplementation on plasma concentrations of glucagon-like peptide-1, peptide YY, adropin, insulin, and leptin in periparturient dairy cows. J Dairy Sci, 98(10):6876-85.
Yolbas S, Kara M, Yildirim A, Gundogdu B, Kalayci M, Aydin S, et al (2014). THU0489 Enho Gene Expression and Serum Adropin Level in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Ann Rheum Dis, 73:352-3.
St‐Onge MP, Shechter A, Shlisky J, Tam CS, Gao S, Ravussin E, et al. (2014). Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring), 22(4):1056-63.
Stein L, Samson W, Yosten G (2015). Identification of a Candidate Adropin Receptor. FASEB J, 29(1 Supplement):997.5.
Gu X, Li H, Zhu X, Gu H, Chen J, Wang L, et al (2015). Inverse Correlation Between Plasma Adropin and ET-1 Levels in Essential Hypertension: A Cross-Sectional Study. Medicine (Baltimore), 94(40):e1712.
Butler AA, Tam CS, Stanhope KL, Wolfe BM, Ali MR, O'Keeffe M, et al (2012). Low circulating adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J Clin Endocrinol Metab, 97(10):3783-91.
Sánchez-de-la-Torre M, Khalyfa A, Sánchez-de-la-Torre A, Martinez-Alonso M, Martinez-García MÁ, Barceló A, et al (2015). Precision medicine in patients with resistant hypertension and obstructive sleep apnea: blood pressure response to continuous positive airway pressure treatment. J Am Coll Cardiol, 66(9):1023-32.
Demircelik B, Kurtul A, Ocek H, Cakmak M, Cetin M, Ureyen C, et al (2015). The Relationship Between Adropin Levels and the Slow Coronary Flow Phenomenon. Ind J Clin Biochem,30(4):412-417.
Yolbas S, Kara M, Yilmaz M, Aydin S, Koca S, editors (2014). Serum adropin level and enho expression in systemic sclerosis. Clinical and experimental rheumatology, clinical & exper rheumatology via santa maria 31, 56126 PISA, ITALY.
Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Cakmak T, et al (2014). A comprehensive immunohistochemical examination of the distribution of the fat-burning protein irisin in biological tissues. Peptides, 61:130-6.
Butler AA, St-Onge M-P, Siebert EA, Medici V, Stanhope KL, Havel PJ (2015). Differential Responses of Plasma Adropin Concentrations To Dietary Glucose or Fructose Consumption In Humans. Sci Rep, 5:14691.
Kheirandish-Gozal L, Gileles-Hillel A, Alonso-Álvarez M, Peris E, Bhattacharjee R, Terán-Santos J, et al (2015). Effects of adenotonsillectomy on plasma inflammatory biomarkers in obese children with obstructive sleep apnea: A community-based study. Int J Obes (Lond), 39(7):1094-100.
Kuloglu T, Aydin S, Eren MN, Yilmaz M, Sahin I, Kalayci M, et al (2014). Irisin: a potentially candidate marker for myocardial infarction. Peptides, 55:85-91.
Kuhla A, Hahn S, Butschkau A, Lange S, Wree A, Vollmar B (2013). Lifelong caloric restriction reprograms hepatic fat metabolism in mice. J Gerontol A Biol Sci Med Sci, 69(8):915-22.
Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, et al (2014). Regulation of substrate oxidation preferences in muscle by the peptide hormone adropin. Diabetes, 63(10):3242-52.
Goetze JP, Albrethsen J (2014). Adropin: a new regulatory peptide in cardiovascular endocrinology. Regul Pept, 190-191:41-2.
Aydin S (2014). Three new players in energy regulation: preptin, adropin and irisin. Peptides, 56:94-110.
Puzio I, Tymicki G, Pawłowska M, Puzio A, Śleboda W (2015). Role of adropin in cardiovascular physiology. Med Weter, 71(10):599-601.
Akcilar R, Kocak FE, Simsek H, Akcilar A, Bayat Z, Ece E, et al editors (2015). Antidiabetic and Hypolipidemic Effects of Adropin in Streptozotocin-induced Type 2 Diabetic Rats. Acta Physiol, wiley –blackwell 111 river st, hoboken 07030-5774, New Jersi, NJ USA.
Aydin S (2013). Presence of adropin, nesfatin-1, apelin-12, ghrelins and salusins peptides in the milk, cheese whey and plasma of dairy cows. Peptides, 43:83-7.
Aydin S, Eren M, Kuloglu T, Aydin S, Yilmaz M, Gul E, et al (2015). Alteration of serum and cardiac tissue adropin, copeptin, irisin and TRPM2 expressions in DOX treated male rats. Biotech Histochem, 90(3):197-205.
Aydin S, Kuloglu T, Aydin S, Eren MN, Yilmaz M, Kalayci M, et al (2013). Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes. Mol Cell Biochem, 380(1-2):73-81.
Aydin S, Kuloglu T, Aydin S, Kalayci M, Yilmaz M, Çakmak T, et al (2014). Elevated adropin: a candidate diagnostic marker for myocardial infarction in conjunction with troponin-I. Peptides, 58:91-7.
Bremer AA, Stanhope KL, Graham JL, Cummings BP, Ampah SB, Saville BR, et al (2014). Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. J Nutr, 144(1):5-11.
Catak Z, Aydin S, Sahin I, Kuloglu T, Aksoy A, Dagli AF (2014). Regulatory neuropeptides (ghrelin, obestatin and nesfatin-1) levels in serum and reproductive tissues of female and male rats with fructose-induced metabolic syndrome. Neuropeptides, 48(3):167-77.
Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA (2015). Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab, 4(4):310-24.
Kuloglu T, Aydin S (2014). Immunohistoche-mical expressions of adropin and ınducible nitric oxide synthase in renal tissues of rats with streptozotocin-ınduced experimental diabetes. Biotech Histochem, 89(2):104-10.
Stein L, Samson W, Yosten G (2014). Adropin Enhances Glucose Disposal and Cardiovascular Function in Rats (LB761).FASEB J, 28(1).
Wang SP, Gao YI, Gang L, Dun D, Chen RJ, Zhang YZ, et al (2015). Molecular cloning, characterization and expression of the energy homeostasis associated gene in piglet. J Zhejiang Univ Sci B, 16(6):524-32.
Wong C-M, Wang Y, Lee JTH, Huang Z, Wu D, Xu A, et al (2014). Adropin is a brain membrane-bound protein regulating physical activity via the NB-3/Notch signaling pathway in mice. J Biol Chem, 289(37):25976-86.
Lovren F, Pan Y, Quan A, Singh K, Shukla P, Al-Omran M, et al (2009). Adropin is a Novel and Potent Endogenous Angiogenic Neuroendocrine Peptide: Abstract # 4746. American College of Cardiology Foundation and the American Heart Association. Michaels Hosp, Toronto, Canada. Circulation, 120:S998.
Lovren F, Pan Y, Quan A, Singh KK, Shukla PC, Al-Omran M, et al (2010). Mechanistic insights into the actions ofadropin, a novel regulator of endothelial function. Can J Cardiol, 26:82D-D.
Lovren F, Pan Y, Quan A, Singh K, Shukla P, Al-Omran M, et al (2010). Adropin is a Novel Regulator of Endothelial Function Through the VEGFR2- PI3K-Akt and VEGFR2- Erk1/2 Pathways: Abstract # 13928. American College of Cardiology Foundation and the American Heart Association. Michael's Hosp, Toronto, Canada. Circulation, 122:A13928.
Niepolski L, Sowinska A, Grzegorzewska A (2015). Circulating Adropin Concentration in Dyslipidemic and Non-Dyslipidemic Hemodialysis Patients: Abstract # 187.9th International Congress of the International Society for Hemodialysis: Global Challenges in Hemodialysis. Kuala Lumpure, Malysia.
Niepolski L, Sowinska A, Grzegorzewska A (2015). Circulating Adropin Concentration in Hemodialysis Patients: Relevance To Endothelial Receptors: Abstract # 119.9th International Congress of the International Society for Hemodialysis: Global Challenges in Hemodialysis. Kuala Lumpure, Malysia.
Niepolski L, Sowinska A, Grzegorzewska A (2015). Circulating Adropin Concentration in Hemodialysis Patients: Relation To Residual Diuresis and Metabolic Disturbances: Abstract # 118.9th International Congress of the International Society for Hemodialysis: Global Challenges in Hemodialysis. Kuala Lumpure, Malysia.
Silva AP, Fragoso A, Guilherme P, Silva C, Santos N, Rato F, et al (2014). FGF-23, mangnesium and adropin as new risk factors of subclinical atherosclerosis in type 2 diabetic with 3 and 4 stages chronic kidney disease. Nephrol Dial Transplant, 29: 431-431.
Tam C, Ravussin E, Onge M-PS, Butler A, editors (2011). A Preliminary Analysis of Serum Adropin Levels in Humans. Obesity, nature publishing group 75 varick st, 9 th flr, New York,NY 10013-1917 USA.
Aydin HI, Eser A, Kaygusuz I, Yildirim S, Celik T, Gunduz S, et al (2016). Adipokine, adropin and endothelin-1 levels in intrauterine growth restricted neonates and their mothers. J Perinat Med, 44(6):669-76.
Kocaoglu C, Buyukinan M, Erdem SS, Ozel A (2015). Are obesity and metabolic syndrome associated with plasma adropin levels in children? J Pediatr Endocrinol Metab, 28(11-12):1293-7.
Altincik A, Sayin O (2015). Evaluation of the relationship between serum adropin levels and blood pressure in obese children. J Pediatr Endocrinol Metab, 28(9-10):1095-100.
Gileles-Hillel A, Alonso-Álvarez ML, Kheirandish-Gozal L, Peris E, Cordero-Guevara JA, Terán-Santos J, et al (2014). Inflammatory markers and obstructive sleep apnea in obese children: the NANOS study. Mediators Inflamm,2014:605280.
Sayın O, Tokgöz Y, Arslan N (2014). Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab, 27(5-6):479-84.
Wilmott RW (2013). Plasma adropin levels in children with obstructive sleep apnea. J Pediatr,163(4):929-31.
Qiu X, He J-R, Zhao M-G, Kuang Y-S, Xu S-Q, Zhang H-Z, et al (2014). Relationship between human cord blood adropin levels and fetal growth. Peptides, 52:19-22.
Baka S, Malamitsi-Puchner A, Briana DD, Boutsikou M, Marmarinos A, Gourgiotis D, et al (2016). Adropin concentrations in term pregnancies with normal, restricted and increased fetal growth. J Matern Fetal Neonatal Med, 29(15):2403-7.
Beigi A, Shirzad N, Nikpour F, Nasli Esfahani E, Emamgholipour S, Bandarian F (2015). Association between serum adropin levels and gestational diabetes mellitus; a case–control study. Gynecol Endocrinol,31(12):939-41.
Aydin S, Celik O, Gurates B, Sahin İ, Ulas M, Yilmaz M, et al (2013). Concentrations of preptin, salusins and hepcidins in plasma and milk of lactating women with or without gestational diabetes mellitus. Peptides, 49:123-30.
Aydin S, Kuloglu T, Aydin S (2013). Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus. Peptides, 47:66-70.
Celik E, Yilmaz E, Celik O, Ulas M, Turkcuoglu I, Karaer A, et al (2013). Maternal and fetal adropin levels in gestational diabetes mellitus. J Perinat Med, 41(4):375-80.
Demircelik B, Cakmak M, Nazli Y, Gurel OM, Akkaya N, Cetin M, et al (2014). Adropin: a new marker for predicting late saphenous vein graft disease after coronary artery bypass grafting. Clin Invest Med, 37(5):E338-44.
Celik A, Balin M, Kobat MA, Erdem K, Baydas A, Bulut M, et al (2013). Deficiency of a new protein associated with cardiac syndrome X; called adropin. Cardiovasc Ther, 31(3):174-8.
Lian W, Gu X, Qin Y, Zheng X (2011). Elevated plasma levels of adropin in heart failure patients. Intern Med, 50(15):1523-27.
Zhao L-P, Xu W-T, Wang L, You T, Chan S-P, Zhao X, et al (2015). Serum Adropin Level in Patients with Stable Coronary Artery Disease. Heart, Lung Circ, 24(10):975-9.
Yu H-y, Zhao P, Wu M-c, Liu J, Yin W (2014). Serum adropin levels are decreased in patients with acute myocardial infarction. Regul Pept, 190 (31):46-9.
Vázquez-Rey E, Kaski JC (2003). Cardiovascular syndrome X and endothelial dysfunction. Rev Esp Cardiol, 56(02):181-92.
Kubes P, Suzuki M, Granger D (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci, 88(11):4651-5.
Wolf A, Zalpour C, Theilmeier G, Wang B-y, Ma A, Anderson B, et al (1997). Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol, 29(3):479-85.
Hogg N, Kalyanaraman B, Joseph J, Struck A, Parthasarathy S (1993). Inhibition of low-density lipoprotein oxidation by nitric oxide Potential role in atherogenesis. FEBS Lett, 334(2):170-4.
Böger RH, Bode-Böger SM, Kienke S, Stan AC, Nafe R, Frölich JC (1998). Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis, 136(1):67-77.
Ignarro L (2002). Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol, 53(4):503-14.
81 Alp NJ, Channon KM (2004). Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol, 24(3):413-20.
Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al (2010). The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol, 56(14):1113-32.
Bayturan O, Tuzcu EM, Lavoie A, Hu T, Wolski K, Schoenhagen P, et al (2010). The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis. Arch Intern Med, 170(5):478-84.
Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al (1997). Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 349(9058):1050-53.
| Files | ||
| Issue | Vol 45 No 12 (2016) | |
| Section | Review Article(s) | |
| Keywords | ||
| Adropin Heart Endothelium Systematic review | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
